Give AG (HAM:M4N)
Germany · Delayed Price · Currency is EUR 1.490
+0.010 (0.68%)
At close: Aug 1, 2025
Sage Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 10.5 | 14.13 | 288.28 | 13.38 | 260.38 | Upgrade | |
Revenue Growth (YoY) | -25.69% | -95.10% | 2055.01% | -94.86% | -11.82% | Upgrade |
Cost of Revenue | 5.38 | 7.03 | 122.45 | -170.51 | 92.39 | Upgrade |
Gross Profit | 5.12 | 7.1 | 165.82 | 183.89 | 167.99 | Upgrade |
Selling, General & Admin | 4.56 | 6.61 | 109.1 | 139.75 | 127.34 | Upgrade |
Other Operating Expenses | 4.01 | 4.8 | 40.66 | 36.45 | 27.21 | Upgrade |
Operating Expenses | 8.69 | 11.52 | 154.87 | 186.02 | 165.56 | Upgrade |
Operating Income | -3.57 | -4.42 | 10.96 | -2.13 | 2.44 | Upgrade |
Interest Expense | - | - | -1.9 | -2 | -1.8 | Upgrade |
Interest & Investment Income | 0.28 | 0.65 | 0.1 | 0.1 | 0.1 | Upgrade |
Currency Exchange Gain (Loss) | -0 | -0.1 | -0.38 | -0.31 | 0.74 | Upgrade |
Other Non Operating Income (Expenses) | - | - | 0.07 | 0.04 | 0 | Upgrade |
EBT Excluding Unusual Items | -3.29 | -3.87 | 8.84 | -4.3 | 1.47 | Upgrade |
Impairment of Goodwill | - | - | - | -0.65 | -0.36 | Upgrade |
Gain (Loss) on Sale of Assets | -1.11 | - | 2.16 | 12.26 | 0.23 | Upgrade |
Pretax Income | -4.21 | -3.63 | 11.01 | 7.31 | 1.34 | Upgrade |
Income Tax Expense | -0.04 | 0.16 | 4.64 | 3.14 | 0.06 | Upgrade |
Earnings From Continuing Operations | -4.17 | -3.79 | 6.37 | 4.17 | 1.27 | Upgrade |
Earnings From Discontinued Operations | -0.07 | - | -2.66 | 4.27 | - | Upgrade |
Net Income to Company | -4.24 | -3.79 | 3.71 | 8.44 | 1.27 | Upgrade |
Minority Interest in Earnings | - | -0.09 | -0.16 | -0.17 | -0.97 | Upgrade |
Net Income | -4.24 | -3.89 | 3.56 | 8.27 | 0.31 | Upgrade |
Net Income to Common | -4.24 | -3.89 | 3.56 | 8.27 | 0.31 | Upgrade |
Net Income Growth | - | - | -57.01% | 2611.47% | -95.18% | Upgrade |
Shares Outstanding (Basic) | 14 | 19 | 19 | 19 | 19 | Upgrade |
Shares Outstanding (Diluted) | 14 | 19 | 19 | 19 | 19 | Upgrade |
Shares Change (YoY) | -25.62% | -4.38% | 0.03% | 0.97% | -0.21% | Upgrade |
EPS (Basic) | -0.31 | -0.21 | 0.18 | 0.43 | 0.02 | Upgrade |
EPS (Diluted) | -0.31 | -0.21 | -0.27 | 0.43 | 0.02 | Upgrade |
EPS Growth | - | - | - | 2585.59% | -95.17% | Upgrade |
Free Cash Flow | -4.48 | 2.01 | 2.5 | -9.25 | 7.45 | Upgrade |
Free Cash Flow Per Share | -0.33 | 0.11 | 0.13 | -0.48 | 0.39 | Upgrade |
Dividend Per Share | - | - | 1.000 | 0.750 | 0.120 | Upgrade |
Dividend Growth | - | - | 33.33% | 525.00% | - | Upgrade |
Gross Margin | 48.80% | 50.26% | 57.52% | 1374.66% | 64.52% | Upgrade |
Operating Margin | -33.97% | -31.26% | 3.80% | -15.91% | 0.94% | Upgrade |
Profit Margin | -40.37% | -27.50% | 1.23% | 61.82% | 0.12% | Upgrade |
Free Cash Flow Margin | -42.70% | 14.22% | 0.86% | -69.16% | 2.86% | Upgrade |
EBITDA | -3.44 | -4.3 | 14.26 | 4.86 | 10.38 | Upgrade |
EBITDA Margin | -32.80% | -30.43% | 4.95% | 36.29% | 3.99% | Upgrade |
D&A For EBITDA | 0.12 | 0.12 | 3.3 | 6.98 | 7.94 | Upgrade |
EBIT | -3.57 | -4.42 | 10.96 | -2.13 | 2.44 | Upgrade |
EBIT Margin | -33.97% | -31.26% | 3.80% | -15.91% | 0.94% | Upgrade |
Effective Tax Rate | - | - | 42.13% | 42.93% | 4.72% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.